These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 14574830)

  • 1. The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder.
    Bouffard R; Hechtman L; Minde K; Iaboni-Kassab F
    Can J Psychiatry; 2003 Sep; 48(8):546-54. PubMed ID: 14574830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
    Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
    Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
    Research Units on Pediatric Psychopharmacology Autism Network
    Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder.
    Reimherr FW; Williams ED; Strong RE; Mestas R; Soni P; Marchant BK
    J Clin Psychiatry; 2007 Jan; 68(1):93-101. PubMed ID: 17284136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
    Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
    Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Weiss M; Hechtman L; Turgay A; Jain U; Quinn D; Ahmed TS; Yates T; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):675-88. PubMed ID: 17979587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, randomized, placebo/active controlled crossover evaluation of the efficacy and safety of Ritalin ® LA in children with attention-deficit/hyperactivity disorder in a laboratory classroom setting.
    Schulz E; Fleischhaker C; Hennighausen K; Heiser P; Oehler KU; Linder M; Haessler F; Huss M; Warnke A; Schmidt M; Schulte-Markworth M; Sieder C; Klatt J; Tracik F
    J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):377-85. PubMed ID: 20973708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.
    Pearson DA; Santos CW; Roache JD; Casat CD; Loveland KA; Lachar D; Lane DM; Faria LP; Cleveland LA
    J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):209-16. PubMed ID: 12544181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting methylphenidate reduces collision rates of young adult drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Davis M; Mikami AY; Singh H; Merkel RL; Burket R
    J Clin Psychopharmacol; 2012 Apr; 32(2):225-30. PubMed ID: 22367664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term side effects of stimulant medication are increased in preschool children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.
    Firestone P; Musten LM; Pisterman S; Mercer J; Bennett S
    J Child Adolesc Psychopharmacol; 1998; 8(1):13-25. PubMed ID: 9639076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of once-a-day extended-release methylphenidate, two-times-daily immediate-release methylphenidate, and placebo in a laboratory school setting.
    Döpfner M; Gerber WD; Banaschewski T; Breuer D; Freisleder FJ; Gerber-von Müller G; Günter M; Hässler F; Ose C; Rothenberger A; Schmeck K; Sinzig J; Stadler C; Uebel H; Lehmkuhl G
    Eur Child Adolesc Psychiatry; 2004; 13 Suppl 1():I93-101. PubMed ID: 15322960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.
    Takahashi N; Koh T; Tominaga Y; Saito Y; Kashimoto Y; Matsumura T
    World J Biol Psychiatry; 2014 Aug; 15(6):488-98. PubMed ID: 24456065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.